



PATENT

Case SO-2842/03-US

#9  
Statement re Seq. List.  
+ Seq. List. 2/11  
6.2.03  
Box - Seq

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

IN RE APPLICATION OF: |

Levine et al. |

GROUP ART UNIT: 1624

SERIAL NUMBER: 09/880,654 |

EXAMINER: U. Winkler

FILED: June 14, 2001 |

DATE: May 19, 2003

MAY 27 2003

TECH CENTER 1600/2900

TITLE: FLUORESCENCE POLARIZATION METHOD FOR DETERMINING  
PROTEASE ACTIVITY

I hereby certify that this correspondence is being  
deposited with the United States Postal Service as  
First Class Mail in an envelope addressed to:  
Mail Stop Sequence, U S Patent and Trademark Office,  
P.O. Box 2327, Arlington, VA 22202 on May 19, 2003  
Linda M. Haley

Linda Haley Date: May 19, 2003

STATEMENT UNDER 37 CFR 1.821 § (f)

Commissioner of Patents and Trademarks  
Washington, D. C. 20231

Sir:

This will confirm that the content of the Paper Copy of the  
Sequence Listing and the Computer Readable Copy of the Sequence  
Listing submitted herewith are the same.

placed  
before  
us.

Please charge any appropriate fees to Deposit Account No. 19-1025.

Respectfully submitted,

Rachel Polster

Rachel Polster  
Registration No. 47,004  
314-274-7354

Pharmacia Corporate Patent Department  
P.O. Box 1027  
St. Louis, MO 63006

# Notice to Comply



Application No.

09/880,654

Examiner

Ulrike Winkler, Ph.D.

Applicant(s)

LEVINE ET AL.

Art Unit

1648

RECEIVED

MAY 27 2003

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: Applicant should follow the format of the attached sample statement to request that the CRF filed in the parent application be used to create a CRF in this application.

### Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**